Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1564-1574

  Jögi, Annika ^a,b   Brennan, Donal J ^c   Rydén, Lisa ^b   Magnusson, Kristina ^d   Fernö, Mårten ^e   Stål, Olle ^f   Borgquist, Signe ^e   Uhlen, Mathias ^g   Landberg, Göran ^a   Påhlman, Sven ^a,b   Pontén, Fredrik ^b   Jirström, Karin ^a,b  

^a Malmö University Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UPPSALA UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

Antibody based proteomics; Breast cancer; Estrogen receptor; Prognosis; RBM3

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN RBM3; RNA BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FOLLOW UP; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; RNA METABOLISM; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RNA INTERFERENCE; RNA-BINDING PROTEINS; TAMOXIFEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 71149089765     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.124     Document Type: Article

References (34)

1. Sutherland LC, Rintala-Maki ND, White RD, et al. RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J Cell Biochem 2005;94:5-24.
2. Burd CG, Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994;265:615-621.
3. Derry JM, Kerns JA, Francke U. RBM3, a novel human gene in Xp11.23 with a putative RNA-binding domain. Hum Mol Genet 1995;4:2307-2311.
4. Wright CF, Oswald BW, Dellis S. Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J Biol Chem 2001;276:40680-40686.
5. Martinez-Arribas F, Agudo D, Pollan M, et al. Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapop-totic Bax gene in human breast cancer. J Cell Biochem 2006;97:1275-1282.
6. Martin-Garabato E, Martinez-Arribas F, Pollan M, et al. The small variant of the apoptosis-associated X-chromosome RBM10 gene is co-expressed with caspase-3 in breast cancer. Cancer Genomics Proteo-mics 2008;5:169-173.
7. Kita H, Carmichael J, Swartz J, et al. Modulation of polyglutamine- induced cell death by genes identified by expression profiling. Hum Mol Genet 2002;11: 2279-2287.
8. Danno S, Nishiyama H, Higashitsuji H, et al. Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun 1997;236:804-807.
9. Baldi A, Battista T, De Luca A, et al. Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol 2003;12:213-218.
10. Sureban SM, Ramalingam S, Natarajan G, et al. Translation regulatory factor RBM3 is a proto-onco-gene that prevents mitotic catastrophe. Oncogene 2008;27:4544-4556.
11. Uhlen M, Bjorling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005;4: 1920-1932.
12. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008;216:387-393.
13. Kampf C, Andersson AC, Wester K, et al. Antibody-based tissue profiling as a tool for clinical proteomics. Clinical Proteomics 2004;1:285-299.
14. Andersson AC, Stromberg S, Backvall H, et al. Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics. J Histochem Cytochem 2006;54:1413-1423.
15. Borgquist S, Holm C, Stendahl M, et al. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008;61:197-203.
16. Helczynska K, Larsson AM, Holmquist Mengelbier L, et al. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008;68:9212-9220.
17. Ryden L, Jonsson PE, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;41:256-264. (Pubitemid 40136540)
18. Rydén L, Stendahl M, Jonsson H, et al. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 2005;89:135-143.
19. Brennan DJ, Jirstrom K, Kronblad A, et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006;12:6421-6431.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
21. Nilsson P, Paavilainen L, Larsson K, et al. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteo-mics 2005;5:4327-4337.
22. Björling E, Lindskog C, Oksvold P, et al. A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2007;7:825-844.
23. Lofstedt T, Jogi A, Sigvardsson M, et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004;279:39223-39231.
24. Wellmann S, Buhrer C, Moderegger E, et al. Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci 2004;117:1785-1794.
25. Kitagawa K, Niikura Y. Caspase-independent mitotic death (CIMD). Cell Cycle 2008;7:1001-1005.
26. Saito Y, Nakagami H, Kurooka M, et al. Cold shock domain protein A represses angiogenesis and lym-phangiogenesis via inhibition of serum response element. Oncogene 2008;27:1821-1833.
27. Dresios J, Aschrafi A, Owens GC, et al. Cold stress-induced protein Rbm3 binds 60S ribosomal subunits, alters microRNA levels, and enhances global protein synthesis. Proc Natl Acad Sci USA 2005;102: 1865-1870.
28. Brennan DJ, Rexhepaj E, O'Brien SL, et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008;14: 2681-2689.
29. Brennan DJ, Kelly C, Rexhepaj E, et al. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics Proteo-mics 2007;4:3-16.
30. EBCTCG. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352: 930-942.
31. Brennan DJ, O'Brien SL, Fagan A, et al. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 2005;5:1069-1083.
32. Salicioni AM, Xi M, Vanderveer LA, et al. Identification and structural analysis of human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins that interact with OVCA1, a candidate tumor suppressor. Genomics 2000;69:54-62.
33. Lifschitz-Mercer B, Elliott DJ, Leider-Trejo L, et al. Absence of RBM expression as a marker of intratubular (in situ) germ cell neoplasia of the testis. Hum Pathol 2000;31:1116-1120.
34. Schreiber L, Lifschitz-Mercer B, Paz G, et al. Lack of RBM expression as a marker for carcinoma in situ of prepubertal dysgenetic testis. J Androl 2003;24:78-84.